Last reviewed · How we verify
NCT06149039
Study on Lymphocyte Subsets of Peripheral Blood in Patients With Nonmyopathic Dermatomyositis Complicated With Pulmonary Interstitial Disease
trial in Dermatomyositis in 120 participants. Status unknown.
30 June 2024
Quick facts
| Lead sponsor | Yanfeng Hou |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 120 |
| Start date | 1 April 2023 |
| Primary completion | 30 June 2024 |
| Estimated completion | 30 June 2024 |
| Sites | 1 location across China |
Conditions studied
- Dermatomyositis — all drugs for Dermatomyositis →
Sponsor
Yanfeng Hou
Who can join
Adults 18 to 70, any sex, with Dermatomyositis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To detect the changes of lymphocyte subsets in peripheral blood of non-myopathic dermatomyositis with pulmonary interstitial disease, classical dermatomyositis with pulmonary interstitial disease, rheumatism with non-inflammatory myopathy with pulmonary interstitial disease and healthy adults among the 4 groups, and to detect the related cytokines secreted by lymphocyte subsets Th1,Th2 and Th17. Clinical features, distribution of peripheral lymphocyte subsets ratio and related cytokine content secreted by each lymphocyte subset were analyzed in each group, so as to explore the pathogenesis characteristics of nonmyopathic dermatomyositis complicated with pulmonary interstitial disease, in order to facilitate clinical guidance for diagnosis and treatment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06149039
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dermatomyositis
Currently open trials in the same condition.
- NCT06672822 — Intralesional Injection of STS in Treatment of Calcinosis · Phase 2 · recruiting
- NCT06698796 — A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies · Phase 3 · recruiting
- NCT06732674 — Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases · NA · recruiting
- NCT06686524 — Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refracto · Phase 1 · recruiting
- NCT07037472 — Photoacoustic/Ultrasound Imaging in Patients of Dermatomyositis With Calcinosis Cutis: Characteristic Findings and Treat · NA · recruiting
Other Yanfeng Hou trials
Trials by the same sponsor.
- NCT06137053 — Effect of Telitacicept on Transitional Regulatory B Cells in Patients With Systemic Lupus Erythematosus · unknown
- NCT06146972 — Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid Arthritis · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06149039 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yanfeng Hou
- Last refreshed: 28 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06149039.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing